681 related articles for article (PubMed ID: 26286337)
21. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
[TBL] [Abstract][Full Text] [Related]
22. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
Perry CM
Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165
[TBL] [Abstract][Full Text] [Related]
23. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
24. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
[TBL] [Abstract][Full Text] [Related]
25. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
26. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
28. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
[TBL] [Abstract][Full Text] [Related]
29. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
30. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
32. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Campo R; DeJesus E; Bredeek UF; Henry K; Khanlou H; Logue K; Brinson C; Benson P; Dau L; Wang H; White K; Flaherty J; Fralich T; Guyer B; Piontkowsky D
Clin Infect Dis; 2013 Jun; 56(11):1637-45. PubMed ID: 23362296
[TBL] [Abstract][Full Text] [Related]
33. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Adams JL; Byrne D; Pepe R; Gray A; Baxter JD
Antivir Ther; 2016; 21(2):175-80. PubMed ID: 26308882
[TBL] [Abstract][Full Text] [Related]
34. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
35. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
36. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
[TBL] [Abstract][Full Text] [Related]
40. No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.
Calza L; Borderi M; Colangeli V; Borioni A; Coladonato S; Granozzi B; Viale P
Infect Dis (Lond); 2020 Apr; 52(4):249-256. PubMed ID: 31876437
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
